$Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse$

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse

Multiple myeloma remains an incurable disease with the usual disease course requiring induction therapy, autologous stem cell transplantation for eligible patients, and long-term maintenance. Risk stratification tools and cytogenetic alterations help inform individualized therapeutic choices for pat...

Full description

Bibliographic Details
Main Authors:	Parva Bhatt, Colin Kloock, Raymond Comenzo
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Current Oncology
Subjects:	relapsed/refractory multiple myeloma immunomodulatory agents proteasome inhibitors monoclonal antibodies autologous stem cell transplant
Online Access:	https://www.mdpi.com/1718-7729/30/2/179

Similar Items

The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
by: José-Ángel Hernández-Rivas, et al.
Published: (2022-01-01)

Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy
by: Jiri Minarik, et al.
Published: (2022-10-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01)

RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY
by: María-Victoria Mateos, et al.
Published: (2015-07-01)

Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
by: Evangelos Terpos, et al.
Published: (2022-10-01)

Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
by: S. V. Semochkin
Published: (2015-10-01)

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
by: Francesca Fazio, et al.
Published: (2022-02-01)

A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study
by: Rafael Ríos-Tamayo, et al.
Published: (2023-12-01)

Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
by: Arthur Bobin, et al.
Published: (2021-10-01)

The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma
by: Mark Sellin, et al.
Published: (2022-08-01)

Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis
by: Xinyuan Gu, et al.
Published: (2023-12-01)

Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma
by: Samantha Pozzi, et al.
Published: (2021-10-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
by: Kazuhito Suzuki, et al.
Published: (2023-11-01)

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
by: Fevzi Fırat Yalnız, et al.
Published: (2017-08-01)

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
by: Bhutani D, et al.
Published: (2017-07-01)

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
by: Xiang Zhou, et al.
Published: (2020-04-01)

Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
by: Danai Dima, et al.
Published: (2023-04-01)

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
by: Ja Min Byun, et al.
Published: (2022-10-01)

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
by: Joseph NS, et al.
Published: (2021-08-01)

Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review
by: Abubakar Tauseef, et al.
Published: (2022-01-01)

Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review
by: Tung-Lung Yang, et al.
Published: (2023-11-01)

Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma
by: Omar Nadeem, et al.
Published: (2024-02-01)

Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
by: Atakan Tekinalp, et al.
Published: (2023-12-01)

The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review
by: Razwana Khanam, et al.
Published: (2023-05-01)

Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience
by: Ludovica Fucci, et al.
Published: (2022-01-01)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2020-08-01)

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain
by: Javier de la Rubia, et al.
Published: (2023-05-01)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
by: Massimo Offidani, et al.
Published: (2021-02-01)

Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
by: Norbert Grzasko, et al.
Published: (2021-11-01)

Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond
by: Boris Bozic, et al.
Published: (2021-10-01)

Pomalidomide in the management of relapsed/refractory multiple myeloma: A review
by: Sergej Semochkin
Published: (2023-08-01)

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
by: Klaus Podar, et al.
Published: (2021-10-01)

Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan
by: Yu-Chin Hung, et al.
Published: (2021-05-01)

Single-Cell Transcriptomes Combining with Consecutive Genomics Reveal Clonal Evolution and Gene Regulatory Networks in Relapsed and Refractory Multiple Myeloma
by: Jiadai Xu, et al.
Published: (2022-01-01)

Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma
by: Monique A. Hartley-Brown, et al.
Published: (2024-03-01)

Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments
by: Luca Cancanelli, et al.
Published: (2023-01-01)